Early Detection Research Network

Chan, Daniel

Contact Information

Email: mailto:dchan@jhmi.edu
Fax: 443-287-6388
EDRN Principal Investigator
1760
None given

To update contact information, please visit the Data Management and Coordinating Center.

Open Protocols

Protocol Name Biomarkers Datasets
Clinical and Analytical Validation of Cancer Biomarkers: Developmental Studies 0 0
Clinical Utility of Urinary CD90 as a Biomarker for Prostate Cancer Detection 1 1
Development and Clinical Validation of Biomarkers for Prostate Cancer 0 0
Ovarian Cancer Detection by Uterine Lavage DNA and Serum Proteins: A Phase 2 Biomarker Study 0 0
Prediction rules for aggressive prostate cancer in AS population 0 0
Prostate-MRI 0 0
Upgrading Reference Set 0 0

Closed Protocols

Protocol Name Biomarkers Datasets
EDRN-WHI Pre-Clinical Colon Ca Specimens 0 9
Liver Rapid Reference Set Application: Hemken - Abbott (2015) 0 0
PCA3 Reference Set Application: T2-Erg-Martin Sanda-Emory (2014) 2 0
PCA3 Validation Study and Urinary Reference Set 2 0
Prostate Rapid Pre-Validation Set 6 0
Prostate Rapid Reference Set Application: Daniel Chan/Patty Beckman- JHU/University of Minnesota (2007) 4 0
Prostate Reference Set Application: proPSA-Dan Chan-JHU (2008) 2 0

Publications

Publication Name PubMed ID Journal
A highly sensitive targeted mass spectrometric assay for quantification of AGR2 protein in human urine and serum. 24251762 J. Proteome Res.
A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. 21419439 J. Urol.
A unique proteolytic fragment of alpha1-antitrypsin is elevated in ductal fluid of breast cancer patient. 19902353 Breast Cancer Res. Treat.
AISAIC: a software suite for accurate identification of significant aberrations in cancers. 24292941 Bioinformatics
An integrated proteomic and glycoproteomic approach uncovers differences in glycosylation occupancy from benign and malignant epithelial ovarian tumors. 28491011 Clin Proteomics
Analysis of serum protein glycosylation by a differential lectin immunosorbant assay (dLISA). 24015777 Clin Proteomics
Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. 17981926 Clin. Chem.
Annexin XI is associated with cisplatin resistance and related to tumor recurrence in ovarian cancer patients. 17982121 Clin. Cancer Res.
Application of traditional clinical pathology quality control techniques to molecular pathology. 18258922 J Mol Diagn
Biomarkers in prostate cancer: what's new? 24626128 Curr Opin Oncol
Cancer biomarker discovery in plasma using a tissue-targeted proteomic approach. 17932335 Cancer Epidemiol. Biomarkers Prev.
Cancer proteomics: in pursuit of "true" biomarker discovery. 16214905 Cancer Epidemiol. Biomarkers Prev.
Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%. 15596190 Urology
Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. 17920110 Gynecol. Oncol.
Comparison of total prostate-specific antigen and derivative levels in a screening population of black, white, and Korean-American men. 15040861 Clin Prostate Cancer
Complexed prostate-specific antigen as a staging tool for prostate cancer: a prospective study in 420 men. 12384158 Urology
Comprehensive analysis of protein glycosylation by solid-phase extraction of N-linked glycans and glycosite-containing peptides. 26571101 Nat. Biotechnol.
Detection and verification of glycosylation patterns of glycoproteins from clinical specimens using lectin microarrays and lectin-based immunosorbent assays. 21975078 Anal. Chem.
Detection of prostate cancer using serum proteomics pattern in a histologically confirmed population. 15076276 J. Urol.
Enzymes and related proteins as cancer biomarkers: a proteomic approach. 17382922 Clin. Chim. Acta
Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml. 12913682 J. Urol.
Expression and clinicopathological significance of oestrogen-responsive ezrin-radixin-moesin-binding phosphoprotein 50 in breast cancer. 17593079 Histopathology
Glycoproteomic analysis of bronchoalveolar lavage (BAL) fluid identifies tumor-associated glycoproteins from lung adenocarcinoma. 23802180 J. Proteome Res.
Glycoproteomics for prostate cancer detection: changes in serum PSA glycosylation patterns. 19035787 J. Proteome Res.
GPQuest: A Spectral Library Matching Algorithm for Site-Specific Assignment of Tandem Mass Spectra to Intact N-glycopeptides. 25945896 Anal. Chem.
Identification of biomarkers for breast cancer in nipple aspiration and ductal lavage fluid. 16322290 Clin. Cancer Res.
Identification of glycoproteins containing specific glycans using a lectin-chemical method. 25837443 Anal. Chem.
Integrated analyses of proteins and their glycans in a magnetic bead-based multiplex assay format. 23099556 Clin. Chem.
Integrated glycoprotein immobilization method for glycopeptide and glycan analysis of cardiac hypertrophy. 26378618 Anal. Chem.
Longitudinal assessment of urinary PCA3 for predicting prostate cancer grade reclassification in favorable-risk men during active surveillance. 28417979 Prostate Cancer Prostatic Dis.
Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naïve Men. 25636659 J. Urol.
Multiplexed Targeted Mass Spectrometry-Based Assays for the Quantification of N-Linked Glycosite-Containing Peptides in Serum. 26451657 Anal. Chem.
Network biology in medicine and beyond. 25140061 Circ Cardiovasc Genet
Predicting prostate cancer biochemical recurrence using a panel of serum proteomic biomarkers. 19157448 J. Urol.
Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis. 12597929 Urology
Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer. 27743489 BJU Int.
ProteinChips: the essential tools for proteomic biomarker discovery and future clinical diagnostics. 16309362 Clin. Chem. Lab. Med.
Proteomic analysis of dunning prostate cancer cell lines with variable metastatic potential using SELDI-TOF. 15264244 Prostate
Proteomic cancer biomarkers from discovery to approval: it's worth the effort. 24646122 Expert Rev Proteomics
Quantification of fragments of human serum inter-alpha-trypsin inhibitor heavy chain 4 by a surface-enhanced laser desorption/ionization-based immunoassay. 16574760 Clin. Chem.
SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. 18024530 Clin. Chem.
Serum fucosylated prostate-specific antigen (PSA) improves the differentiation of aggressive from non-aggressive prostate cancers. 25553114 Theranostics
Suppression of annexin A11 in ovarian cancer: implications in chemoresistance. 19484149 Neoplasia
The prostate health index selectively identifies clinically significant prostate cancer. 25463993 J. Urol.
The road from discovery to clinical diagnostics: lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers. 20962299 Cancer Epidemiol. Biomarkers Prev.
Tissue proteomics using chemical immobilization and mass spectrometry. 25283129 Anal. Biochem.
Tyramide signal amplification for antibody-overlay lectin microarray: a strategy to improve the sensitivity of targeted glycan profiling. 21133419 J. Proteome Res.
Updating risk prediction tools: a case study in prostate cancer. 22095849 Biom J
Validation of a multiplex immunoassay for serum angiogenic factors as biomarkers for aggressive prostate cancer. 22722017 Clin. Chim. Acta

To update protocols, publications, biomarkers, or science data, please contact the Informatics Center.